[HTML][HTML] Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations

LN Toksvang, SHR Lee, JJ Yang, K Schmiegelow - Leukemia, 2022 - nature.com
Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is
essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with …

Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis

A Jena, DK Jha, P Kumar-M, KS Kasudhan… - Expert Review of …, 2021 - Taylor & Francis
Background: Prevalence and impact of thiopurine S-methyltransferase (TPMT) and Nudix
hydrolase (NUDT15) minor allele frequencies in South Asian population is unclear …

Pharmacogenetics of childhood acute lymphoblastic leukemia

E Lopez-Lopez, A Gutierrez-Camino… - …, 2014 - Taylor & Francis
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries.
Although treatment outcome has improved owing to advances in chemotherapy, there is still …

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia

T Adam de Beaumais, E Jacqz-Aigrain - European journal of clinical …, 2012 - Springer
Background The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in
children includes 6-mercaptopurine (6-MP). Intracellular metabolism of this prodrug is a key …

[HTML][HTML] Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism

H Kim, HJ Kang, HJ Kim, MK Jang, NH Kim, Y Oh… - 2012 - journals.plos.org
Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics.
To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes …

[HTML][HTML] Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and …

Y Lee, EJ Jang, HY Yoon, J Yee, HS Gwak - Pharmaceuticals, 2022 - mdpi.com
6-Mercaptopurine (6-MP) is a cornerstone of the maintenance regimen for pediatric acute
lymphoblastic leukemia (ALL). Inosine triphosphate pyrophosphatase (ITPA) is considered a …

[HTML][HTML] Association of NUDT15 c.415C>T and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based …

S Kodidela, P Dorababu, DN Thakkar, B Dubashi… - Genes, 2020 - mdpi.com
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the
chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often …

Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL

P Dorababu, SM Naushad, VG Linga… - …, 2012 - Taylor & Francis
Aim: The rationale of this study was to explore the contribution of genetic variants of the
folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in …

Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia

SM Naushad, P Dorababu, Y Rupasree… - Cancer Chemotherapy …, 2019 - Springer
Purpose The rationale of the current study was to develop 6-mercaptopurine (6-MP)-
mediated hematological toxicity prediction model for acute lymphoblastic leukemia (ALL) …

Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects

F Azimi, Y Mortazavi, S Alavi, M Khalili, A Ramazani - Leukemia research, 2015 - Elsevier
Mercaptopurine (6-MP) plays an important role in treatment of childhood acute
lymphoblastic leukemia (ALL). Inosine triphosphate pyrophosphohydrolase (ITPA) is an …